Research
Hormonal
Adipose tissue-derived extracellular vesicles (EVs) mediate communication between adipose tissue and other organs (like the liver), contributing to insulin resistance and systemic metabolic dysfunction in obesity.
Your fat cells are not just storage; they send signals to your liver and other organs via tiny vesicles. In obesity, these signals can promote insulin resistance. Improving your metabolic health through diet and exercise can normalize these signals, reducing the burden on your body's regulatory systems.
GoodSupportsHIGH confidence
Recent studies investigating the role of EVs in the regulation of systemic metabolism have identified adipocyte-derived EVs as mediators linking adiposity and insulin resistance in peripheral tissues, such as the liver [40, 41].
Why this rating
Supported by multiple studies cited in the review, though the paper notes that precise cargo content and mechanisms require further elucidation.
Source
Extracellular vesicles in metabolic disease
Naveed Akbar et al. · Diabetologia · 2019
DOI 10.1007/s00125-019-05014-5
narrative_reviewCited 182×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity and metabolic dysfunction are associated with significantly elevated circulating levels of extracellular vesicles (EVs), particularly those derived from platelets, endothelial cells, and adipocytes, which serve as biomarkers for metabolic stress and insulin resistance.Good
- Adipose tissue macrophage (ATM)-derived EVs containing miR-155 contribute to glucose intolerance and insulin resistance by suppressing adipogenic transcription factors PPARγ and CEBPβ.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →